Stephens & Co. analyst Matt Breese downgrades OceanFirst Financial (NASDAQ:OCFC) from Overweight to Equal-Weight.
Freeline Therapeutics FY21 EPS $(3.93) Up From $(6.81) YoY
Freeline Therapeutics (NASDAQ:FRLN) reported quarterly losses of $(3.93) per share. This is a 42.29 percent increase over losses of $(6.81) per share from the same period last year.